Viking Therapeutics (VKTX) Earns Media Sentiment Rating of 0.37

Media stories about Viking Therapeutics (NASDAQ:VKTX) have trended positive on Thursday, AlphaOne Sentiment reports. The research group, a service of Accern, identifies positive and negative media coverage by monitoring more than twenty million blog and news sources. AlphaOne ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Viking Therapeutics earned a media sentiment score of 0.37 on AlphaOne’s scale. AlphaOne also gave media coverage about the company an impact score of 0 out of 100, meaning that recent media coverage is extremely unlikely to have an impact on the company’s share price in the next several days.

Several research analysts have commented on VKTX shares. Maxim Group set a $5.00 target price on Viking Therapeutics and gave the stock a “buy” rating in a research note on Saturday, February 11th. HC Wainwright restated a “buy” rating and issued a $5.00 target price on shares of Viking Therapeutics in a research note on Monday, March 27th.

Shares of Viking Therapeutics (NASDAQ:VKTX) traded down 1.40% on Thursday, reaching $1.41. The company’s stock had a trading volume of 10,741 shares. Viking Therapeutics has a 12-month low of $0.90 and a 12-month high of $1.80. The company’s market capitalization is $33.59 million. The company’s 50-day moving average is $1.36 and its 200 day moving average is $1.27.

Viking Therapeutics (NASDAQ:VKTX) last posted its quarterly earnings results on Tuesday, March 21st. The company reported ($0.18) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.20) by $0.02. Equities analysts anticipate that Viking Therapeutics will post ($0.71) earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: This story was originally reported by sleekmoney and is the property of of sleekmoney. If you are viewing this story on another domain, it was illegally copied and republished in violation of United States and international copyright & trademark law. The legal version of this story can be accessed at

Viking Therapeutics Company Profile

Viking Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapies for metabolic and endocrine disorders. The Company’s clinical program, VK5211, is an orally available drug candidate, which is in Phase II clinical trial for acute rehabilitation following non-elective hip fracture surgery.

5 Day Chart for NASDAQ:VKTX

This story was originally published by sleekmoney ( and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at

Receive News & Ratings for Viking Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viking Therapeutics Inc and related companies with's FREE daily email newsletter.


Leave a Reply

Your email address will not be published. Required fields are marked *